Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider - Gilde Healthcare

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

July 5, 2024
Katwijk & Spijkenisse (the Netherlands)

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in the healthcare market. Strengthening their joint position will further elevate service levels and product offerings of both companies. The combination aims to maintain current service offerings and respect existing organizations, brands and partners. Integration will be done carefully, with the existing management teams and no changes to operations in Katwijk and Spijkenisse.

Ronald Holtzer, CEO of EetgemakWe are excited to join forces with TotaalVERS, together we create a full-service “one stop shop” for our current and future customers.”

Ronald van der Leer, CEO of TotaalVERS: “This partnership marks an important milestone in our history and reaffirms our commitment to quality, service and innovation in the healthcare market and other channels.” 

*The combination of TotaalVERS and Eetgemak is subject to approval from the ACM

About TotaalVERS
Founded in 2004 in Spijkenisse, TotaalVERS is an integrated producer and supplier of convenience meals, ingredients and groceries. Praised for its high service level, the company serves care & cure clients in the South-West of the Netherlands. The company has a state-of-the-art production and warehouse facility housing c. 125 employees. For more information, visit the company’s website at www.totaalvers.nl

About Eetgemak
Eetgemak is a leading producer and supplier of fresh, made-to-order meals, meal components and dietary meals. The organization supplies the care & cure sector in the Netherlands with over 40k meals per day. Gilde invested in the company in 2019 and is supporting Eetgemak in the expansion of its market position, through growth in existing and new markets. For more information, visit the company’s website at www.eetgemakgroep.nl

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com

 

More news

Gilde Healthcare Company Volta Medical publishes RESTART Trial Results on AI Solutions in Recurrent Atrial Fibrillation

Volta Medical’s artificial intelligence (AI) solution demonstrated 83% freedom from atrial fibrillation (AF) at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation Volta Medical, committed...
February 3, 2026

Gilde Healthcare backed MedTech Group acquires precision surgical instruments and implants contract manufacturer Rudischhauser

Gilde Healthcare’s Surgical Instrument Contract Manufacturing Group (“the Group”) has acquired Rudischhauser Surgical Instruments Manufacturing GmbH (“Rudischhauser”), marking a significant milestone in the creation of a leading contract manufacturing group for precision surgical instruments. Rudischhauser...
January 26, 2026

Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease

First dose-expansion patient successfully received SB-007  SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations  SB-007 granted FDA Fast Track designation, following previously received Orphan Drug...
January 9, 2026